Key Highlights: Phase 1/2 safety cohort enrollment complete: Eight (8) patients with invasive oral cavity cancer treated in the PRV211 safety cohort Primary safety endpoint met: Safety assessed by clinical laboratory evaluations and/or clinical examination at 1-month post-surgery...
Hence then, the article about privo technologies announces milestone in prv211 arm of cln 004 clinical trial primary endpoint met no serious adverse events reported was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Privo Technologies Announces Milestone in PRV211 Arm of CLN-004 Clinical Trial: Primary Endpoint Met; No Serious Adverse Events Reported )
Also on site :
- Belgium corrects US on ‘peace board’ claim
- Grey's Anatomy Brings Back Meredith And Nick For A Tense Reunion — And A Big Question About Their Future
- Trump says US still ‘watching Iran‘ as ‘massive’ fleet heads to Gulf region